5 Gastroenterology Headlines You Missed in November 2025

November brought a wave of notable updates across gastroenterology, marked by regulatory milestones, evolving clinical guidance, and new research shaping patient care. The month opened with the US Food and Drug Administration’s first-ever approval of a treatment for irritable bowel syndrome with constipation (IBS-C) in children ≥ 7 years of age, followed quickly by 52-week safety findings presented at the 2025 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting. Meanwhile, the American Gastroenterological Association released its updated living guideline for moderate-to-severely active Crohn’s disease, reflecting the rapid expansion of high-efficacy therapeutic options and emphasizing early intervention to optimize long-term outcomes.